These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3376887)

  • 21. Mexiletine and quinidine in combination in an ischemic model: supra-additive antiarrhythmic and electrophysiologic actions.
    Duff HJ; Gault NJ
    J Cardiovasc Pharmacol; 1986; 8(4):847-57. PubMed ID: 2427828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting ventricular tachycardia cycle length after procainamide by assessing cycle length-dependent changes in paced QRS duration.
    Marchlinski FE; Buxton AE; Josephson ME; Schmitt C
    Circulation; 1989 Jan; 79(1):39-46. PubMed ID: 2910546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
    Rae AP; Spielman SR; Kutalek SP; Kay HR; Horowitz LN
    Am J Cardiol; 1987 Feb; 59(4):291-5. PubMed ID: 3544793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of aprindine on monophasic action potentials.
    Matsumoto K; Dohi Y; Asano Y; Kaneko K
    J Electrocardiol; 1991 Apr; 24(2):113-20. PubMed ID: 2037813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide.
    Windle J; Prystowsky EN; Miles WM; Heger JJ
    Clin Pharmacol Ther; 1987 Jun; 41(6):603-10. PubMed ID: 3581646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electropharmacologic testing in sustained ventricular tachycardia associated with coronary heart disease: value of the response to intravenous procainamide in predicting the response to oral procainamide and oral quinidine treatment.
    Oseran DS; Gang ES; Rosenthal ME; Mandel WJ; Peter T
    Am J Cardiol; 1985 Nov; 56(13):883-6. PubMed ID: 3904387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic and clinical factors influencing response to class IA antiarrhythmic agents in patients with inducible sustained monomorphic ventricular tachycardia.
    Gold RL; Haffajee CI; Alpert JS
    Am Heart J; 1986 Jul; 112(1):9-13. PubMed ID: 3728294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for a reexcitability gap in man after treatment with type I antiarrhythmic drugs.
    Haberman RJ; Rials SJ; Stohler JL; Marinchak RA; Kowey PR
    Am Heart J; 1993 Nov; 126(5):1121-6. PubMed ID: 8237754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans.
    Nademanee K; Stevenson WG; Weiss JN; Frame VB; Antimisiaris MG; Suithichaiyakul T; Pruitt CM
    Circulation; 1990 Mar; 81(3):790-6. PubMed ID: 2306831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities.
    Horowitz LN; Greenspan AM; Spielman SR; Josephson ME
    Circulation; 1981 May; 63(5):1120-8. PubMed ID: 7471373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent.
    Bargheer K; Bode F; Klein HU; Trappe HJ; Franz MR; Lichtlen PR
    Eur Heart J; 1994 Oct; 15(10):1409-14. PubMed ID: 7821321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.
    Klein RC; Huang SK; Marcus FI; Horwitz L; Fenster PE; Rushforth N; Kirsten EB
    Am Heart J; 1987 Sep; 114(3):551-8. PubMed ID: 3630896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML; Rasmussen HS; Cobbe SM
    Am J Cardiol; 1992 Dec; 70(18):1432-7. PubMed ID: 1442614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinidine for ventricular arrhythmias: value of electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1983 Jan; 51(1):90-5. PubMed ID: 6849270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation.
    Echt DS; Black JN; Barbey JT; Coxe DR; Cato E
    Circulation; 1989 May; 79(5):1106-17. PubMed ID: 2469545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias.
    Aronow WS; Mercando AD; Epstein S; Kronzon I
    Am J Cardiol; 1990 Aug; 66(4):423-8. PubMed ID: 2386118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapy.
    Mitchell LB; Hubley-Kozey CL; Smith ER; Wyse DG; Duff HJ; Gillis AM; Horacek BM
    Circulation; 1992 Aug; 86(2):383-93. PubMed ID: 1638707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia.
    Myerburg RJ; Kessler KM; Kiem I; Pefkaros KC; Conde CA; Cooper D; Castellanos A
    Circulation; 1981 Aug; 64(2):280-90. PubMed ID: 7249296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.